Wells Fargo
GYRE icon

Wells Fargo’s Gyre Therapeutics GYRE Stock Holding History

Wells Fargo’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.9K Sell
4,290
-8,629
-67% -$67K ﹤0.01% 5629
2025
Q4 		$91.2K Buy
12,919
+7,361
+132% +$56.8K ﹤0.01% 5419
2025
Q3 		$41.5K Sell
5,558
-1,457
-21% -$11.1K ﹤0.01% 5606
2025
Q2 		$51.6K Buy
7,015
+2,907
+71% +$25.4K ﹤0.01% 5492
2025
Q1 		$31.7K Buy
4,108
+92
+2% +$1.01K ﹤0.01% 5548
2024
Q4 		$48.6K Buy
4,016
+913
+29% +$11.7K ﹤0.01% 5493
2024
Q3 		$38.9K Buy
3,103
+116
+4% +$1.5K ﹤0.01% 5434
2024
Q2 		$35.6K Buy
2,987
+2,891
+3,011% +$39.7K ﹤0.01% 5411
2024
Q1 		$1.68K Buy
96
+2
+2% +$36 ﹤0.01% 6064
2023
Q4 		$2.42K Buy
94
+81
+623% +$1.15K ﹤0.01% 6073
2023
Q3 		$97 Hold
13
– – ﹤0.01% 6781
2023
Q2 		$67 Buy
13
+1
+8% +$4 ﹤0.01% 6972
2023
Q1 		$38 Sell
12
-12
-50% -$46 ﹤0.01% 7187
2022
Q4 		$95 Buy
24
+1
+4% +$4 ﹤0.01% 6807
2022
Q3 		$0 Sell
23
-3
-12% -$38 ﹤0.01% 6916
2022
Q2 		$0 Sell
26
-38
-59% -$253 ﹤0.01% 7062
2022
Q1 		$0 Hold
64
– – ﹤0.01% 7344
2021
Q4 		$0 Hold
64
– – ﹤0.01% 7450
2021
Q3 		$2K Sell
64
-3
-4% -$99 ﹤0.01% 6570
2021
Q2 		$2K Sell
67
-7,431
-99% -$255K ﹤0.01% 6539
2021
Q1 		$283K Sell
7,498
-1,300
-15% -$59.4K ﹤0.01% 4997
2020
Q4 		$416K Buy
8,798
+5,873
+201% +$254K ﹤0.01% 4651
2020
Q3 		$94K Buy
2,925
+1,405
+92% +$55K ﹤0.01% 5292
2020
Q2 		$67K Buy
1,520
+1,199
+374% +$56.3K ﹤0.01% 5392
2020
Q1 		$10K Sell
321
-406
-56% -$18.7K ﹤0.01% 5745
2019
Q4 		$37K Sell
727
-466
-39% -$19.5K ﹤0.01% 5601
2019
Q3 		$44K Sell
1,193
-3,540
-75% -$191K ﹤0.01% 5593
2019
Q2 		$262K Sell
4,733
-946
-17% -$59.1K ﹤0.01% 4816
2019
Q1 		$346K Sell
5,679
-56
-1% -$3.6K ﹤0.01% 4546
2018
Q4 		$340K Sell
5,735
-985
-15% -$72.6K ﹤0.01% 4590
2018
Q3 		$544K Buy
6,720
+2,156
+47% +$171K ﹤0.01% 4379
2018
Q2 		$399K Buy
4,564
+3,372
+283% +$591K ﹤0.01% 4624
2018
Q1 		$231K Buy
1,192
+712
+148% +$133K ﹤0.01% 4902
2017
Q4 		$49K Buy
+480
New +$24.5K ﹤0.01% 5564
2017
Q3 		– Hold
0
– – – 6365
2017
Q2 		– Sell
-67
Closed -$2.4K – 6311
2017
Q1 		$5K Buy
+67
New +$3.91K ﹤0.01% 6024
2016
Q4 		– Hold
0
– – – 6332
2016
Q3 		– Hold
0
– – – 6243
2016
Q2 		– Hold
0
– – – 6191
2016
Q1 		– Hold
0
– – – 6289
2015
Q4 		– Hold
0
– – – 6303
2015
Q3 		– Hold
0
– – – 6297
2015
Q2 		– Hold
0
– – – 6412
2015
Q1 		– Hold
0
– – – 6240
2014
Q4 		– Hold
0
– – – 6288
2014
Q3 		– Hold
0
– – – 6233
2014
Q2 		– Hold
0
– – – 6181
2014
Q1 		– Hold
0
– – – 5948
2013
Q4 		– Hold
0
– – – 5810
2013
Q3 		– Hold
0
– – – 5722
2013
Q2 		– Hold
0
– – – 5627

Other funds holding GYRE

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Wells Fargo's GYRE Position: Q1 2026 in Review

Wells Fargo reduced its Gyre Therapeutics (GYRE) stake by 67% in Q1 2026, selling an estimated $67K and leaving 4,290 shares worth $29.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5629.

Wells Fargo first reported a position in GYRE in Q1 2017 and has held it in 35 quarters since. The position peaked at $544K in Q3 2018. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

  • Wells Fargo held 4,290 shares of Gyre Therapeutics worth $29.9K as of Q1 2026.
  • Wells Fargo sold 8,629 Gyre Therapeutics shares in Q1 2026, an estimated $67K.
  • Gyre Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5629 holding.
  • Wells Fargo first reported a position in Gyre Therapeutics in Q1 2017 and has held it in 35 quarters since.
  • Wells Fargo's Gyre Therapeutics position peaked at $544K in Q3 2018.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.